Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. GOOG
6. AMD
7. INTC
8. CSX
9. IBM
10. KNX

Go back to Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
(NASDAQ: ALEC) Delayed: 1.49 -0.04 (2.61%)
Previous Close $1.53    52 Week High $ 
Open $1.48    52 Week Low $ 
Day High $1.55    P/E N/A 
Day Low $1.47    EPS $ 
Volume 607,112